↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Kkr & Co$KKR · filed: saw revenue fall 11.0% in FY2025 to $19.5BNext year $9.7B–$49.2B sealedCheck ▾Close ▴
What Kkr & Co filed
Saw revenue fall 11.0% in FY2025 to $19.5 billion, equity 7.5% of assets, and dividend per share up 7 years running. Every figure links to the filing it came from on Kkr & Co’s card.
What the house said in advance
Revenue for the fiscal year after 2025-12-31 between $9.7B and $49.2B, an 80% range sealed on 26 Sept 2026 · receipt #451d61 · graded in public by the revenue in Kkr & Co’s next annual report.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
KKR's Integer close anchored a **$37.2B** August for global PE, down **43%** YoY, with healthcare taking **32%** share as financing costs and LP fatigue crush broader deal flow.
$5.89 billion
acquisition of Integer Holdings in the final week of…
43%
year-over-year to
$37.2 billion
across 189 announced transactions
$34 billion
Envision Healthcare exit in 2018—accounted for nearly
KKR & Co. completed its $5.89 billion acquisition of Integer Holdings in the final week of August, capping a month in which global private equity deal volume fell 43% year-over-year to $37.2 billion across 189 announced transactions. The Integer close—KKR's largest healthcare take-private since its $34 billion Envision Healthcare exit in 2018—accounted for nearly 16% of the month's entire buyout volume and pushed healthcare to $11.8 billion in August PE activity, more than financials and technology combined.
Integer, a Plano-based medical device contract manufacturer serving cardiac rhythm management and neuromodulation markets, had traded publicly since 2011 under ticker ITGR. KKR paid $108 per share in cash, a 31% premium to the 30-day volume-weighted average before deal announcement in May. The firm inherits $1.9 billion in trailing twelve-month revenue, 18 manufacturing facilities across five countries, and longstanding supply relationships with Medtronic, Abbott, and Boston Scientific. Integer's management stays intact. CEO Joe Flanagan, who navigated the 2023 spin-off of the Electrochem battery division, reports to KKR partner Gaurav Trehan and the healthcare investment committee led by Trent Edwards.
The collapse in August PE volume reflects three compounding pressures. First, elevated financing costs: the average leveraged loan for a US buyout priced at SOFR plus 475 basis points in August, up from 425 in Q2 and the highest cost of debt for sponsor-backed LBOs since October 2023. Second, exit market dysfunction—only $14.3 billion in PE-backed IPO and strategic sale exits cleared in August globally, the slowest month since December 2022. Third, allocator fatigue: limited partners called $62 billion less capital to PE funds in the first eight months of 2024 versus the comparable 2023 period, according to Preqin, forcing GPs to preserve dry powder and walk from auctions where seller expectations haven't reset. KKR sidestepped all three by financing Integer with a $3.1 billion term loan B arranged in-house, no syndication risk, and by locking the deal in May when SOFR forwards implied cheaper future funding.
Healthcare's resilience is structural, not cyclical. Of the $11.8 billion in August healthcare PE deals, $8.4 billion targeted medical devices or healthcare IT, sub-sectors with recurring revenue models, high EBITDA margins above 22%, and limited reimbursement exposure. Integer fits the archetype: 64% gross margins, 87% customer retention, and a product portfolio immune to Medicare fee schedule volatility. KKR has deployed $19.3 billion into healthcare since 2021, more than any other sector, with a strategic tilt toward non-hospital infrastructure—imaging centers, ambulatory surgery, device OEMs—that benefit from demographic tailwinds without staffing or regulatory risk. The firm's existing portfolio company Cotiviti, a healthcare analytics platform acquired in 2018 for $4.9 billion, already integrates claims data from Integer's end customers, creating an adjacency play KKR will likely exploit by 2026.
Operators should track three follow-on events. First, Integer's post-close deleveraging path: the company entered the deal with $847 million in net debt and KKR added roughly $3.8 billion in acquisition financing, pushing pro forma leverage to approximately 5.1x trailing EBITDA. Management guided to $220 million in 2024 adjusted EBITDA during the May announcement; any miss forces either asset sales or margin compression. Second, watch for KKR's next move in the medical device supply chain—rumors circulate that the firm is evaluating bids for Nevro, the $1.2 billion market-cap neuromodulation manufacturer, which would pair cleanly with Integer's existing spinal cord stimulator component business. Third, the September Preqin LP survey will quantify whether healthcare's August outperformance translates to increased sector-specific fundraising, or whether it simply reflects GPs chasing the only deals that clear internal return hurdles in a compressed market.
Integer's bondholders tendered $843 million of existing notes at 101.5 cents on the dollar in the change-of-control offer that closed August 28, leaving KKR with a clean capital structure and no legacy covenants. The excess cash went back to KKR's North America Fund XIII, which wrote the equity check and now owns 100% of a business generating $18.50 of free cash flow per share at run-rate, implying a 5.8x multiple on unlevered FCF—tight, but defensible if the neuromodulation market grows at the 11% CAGR Integer's bankers modeled through 2028.
Branded by POPS4 · proof in 60 seconds
For the principal
Integer's 5.1x post-deal leverage and $220M EBITDA guide create refinancing risk by 2027; hedge with healthcare IT or non-hospital infrastructure allocations.
For the operator
Track Nevro bid rumors and Integer's Q4 margin print; any EBITDA miss below $220M triggers covenant pressure and potential portfolio company fire sales.
For the house
Increased healthcare device exposure through Alpine MedTech sleeve; watching for KKR secondary opportunities if Integer underperforms and forces GP liquidity by mid-2025.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.